Fareon Announces New Paper Linking Biomarkers for Lower Predicted Brain Age, Reduced Inflammation, and Activation of Repair to Its Noninvasive Biophysics TreatmentPlasma proteomics data reveal biological changes in people receiving Fareon Restore™ at home, supporting the potential to treat brain disorders through magnetic fields
Fareon Announces Oral Presentation of First-in-Class Biophysics Treatment Results in Patients with Cognitive Impairment from Long COVID at the 2026 ISLC-PAIS Annual MeetingSAN FRANCISCO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Fareon, a clinical-stage biophysics company pioneering novel therapies for brain disorders, brain injuries, and neurodevelopmental conditions, today announced that results of a clinical study evaluating its Fareon Restore™ biophysics platform in people with persistent, debilitating Long COVID brain fog will be presented at the International Society for Long COVID and Post-Acute Infection Syndromes (ISLC-PAIS) Annual Meeting, held August 26-29, 2026 in Amsterdam.
